[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Gantosj "$CRDL in a consolidation mode above its 200MA after the XXX% move from the 52W low We are waiting for the #Myocarditis data in this Q. Meanwhile the Ph-3 trial in acute #Pericarditis continue to recruit patients"
@Gantosj on X 2025-07-03 14:22:05 UTC 13.3K followers, 3245 engagements

"$EPRX is emerging as one of 2025s standout performers. The stock has officially broken out of its "Flag formation" & clearing the weekly resistance at $XXXX. Next testing the 52-week high with target set on a New52W-High as we approach the Ph-2a data release in September. All signals point to strength building ahead of the next major catalyst. 🚀📈"
@Gantosj on X 2025-07-24 17:59:06 UTC 13.3K followers, 1737 engagements

"$EPRX is using the "Cohort-8" dose based on the Safety Review Committee that conducted a comprehensive review of all safety PK and efficacy data collected to date in all dose cohorts of the open label study including importantly the 4-week data from cohort X. Based on this review the Committee expressed confidence in the results from the safety and clinical efficacy outcomes of the cohort X dose and recommended its use as the first of the two active doses of the Ph-2b randomized placebo-controlled portion of the study"
@Gantosj on X 2025-07-08 19:56:29 UTC 13.3K followers, 2122 engagements

"$MSCL.TO $MSCLF is aiming to bring back muscles via 'Muscles Regeneration'"
@Gantosj on X 2025-05-05 15:46:00 UTC 13.3K followers, 2114 engagements

"$SRPT Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term Sustainable Growth and Provides Update on ELEVIDYS Label"
@Gantosj on X 2025-07-16 20:03:12 UTC 13.3K followers, 4221 engagements

"And $VLTLF $LIB is breaking out the 200MA on a huge volume both in the US & Canada Is it the inflection point $VLT:F's investors were waiting for Let's see what they have in the next few weeks"
@Gantosj on X 2025-07-18 19:59:43 UTC 13.3K followers, 2993 engagements

"$CRDLs current valuation barely reflects the significant progress in its #pericarditis program which has already advanced to Ph-3. If the upcoming Ph-2 #myocarditis data turns out positive the stock could see a rapid re-rating to the upside. The Ph-3 trial for recurrent pericarditis is considered highly de-risked thanks to the robust results from the earlier open-label Ph-2 study which closely mirrors the approach used by an already approved IL-1 blocker"
@Gantosj on X 2025-07-22 13:53:13 UTC 13.3K followers, 3969 engagements

"And the first breakout is here $CRDL breaking out the $XXXX resistance line & heading north to test the 200MA around $1.45"
@Gantosj on X 2025-06-04 17:23:36 UTC 13.3K followers, 2571 engagements

"$SRPT Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants X Years Old at Time of Treatment"
@Gantosj on X 2025-05-16 13:02:45 UTC 13.3K followers, 7860 engagements

"The day the street understands that $VLTLF $LIB's DLE is the cheapest way in the world to extract #Lithium which is a critical mineral for the US where China controls XX% of the world production then US Government will push $VLTLF & support their DEL"
@Gantosj on X 2025-07-18 15:19:49 UTC 13.3K followers, 4398 engagements

"$CNVIF $CNVI Conavi Medical Applauds New American Journal of Cardiology Study Highlighting Importance of Intracoronary Imaging During PCI"
@Gantosj on X 2025-07-23 11:20:07 UTC 13.3K followers, 2870 engagements

"$CRDL Topline results are expected within the next two weeks. Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute #Myocarditis"
@Gantosj on X 2025-07-22 11:33:32 UTC 13.3K followers, 2679 engagements

"$CNVI.v $CNVIF's CEO: "The market risk is really low at this level. In fact it's a hot time in the market for products like ours. Our technology risk has been retired with regard to our next generation development & regulatory risk will be low because we have a 510K application with our own product at as its predicate and lastly our our finance or capital risk has been reduced because we have just raised $XX million in financing.""
@Gantosj on X 2025-07-03 18:22:02 UTC 13.3K followers, 2234 engagements

"Strong performance for $VLTLF $LIB today up XXXXX% on robust volume. 397K in the US and over 656K in Canada It certainly appears that sophisticated investors are stepping in and loading up signaling renewed confidence and momentum in the stock. #StockMarket #Investing #Lithium #Minerals #RareEarths"
@Gantosj on X 2025-07-18 18:46:20 UTC 13.3K followers, 7160 engagements

"Nice $ASTS at $XXXX is a great point to be my friend Keep holding tight we can sell those shares for several 100s dollars in 2027-2028 😇"
@Gantosj on X 2025-07-17 15:46:35 UTC 13.3K followers, 2037 engagements

"Great move by $CRDL up XX% after the news this morning locking database from its Ph-2 pericarditis trail & topline results within X weeks"
@Gantosj on X 2025-07-22 16:11:42 UTC 13.3K followers, 2045 engagements

"$SRPT Sarepta Therapeutics to Announce First Quarter 2025 Financial Results Tuesday May X 2025. and conference call at 4:30pm ET"
@Gantosj on X 2025-04-22 12:57:43 UTC 13.3K followers, 1940 engagements

"$CRDL bouncing up from its 50MA after X weeks of consolidation with high volume of 150K shares in the 1st XX minutes Waiting for the myocarditis data"
@Gantosj on X 2025-05-28 13:44:52 UTC 13.3K followers, 1728 engagements

"The $1.25B $PFE deal with Chinas 3SBio highlights big pharmas aggressive pursuit of bi-specific drugs to gain a competitive edge in cancer therapy This underscores the huge potential of $MDNA.to $MDNAF's MDNA113 a first-in-class tumor-targeting conditionally activated anti-PD1-IL-2 Superkine. Designed to enhance the therapeutic index MDNA113 combines PD-1 blockade with a tumor-specific IL-2 Superkine to boost T-cell/NK cell activity in cold tumors like glioblastoma and pancreatic cancer with preclinical data showing potent immune activation. As bispecifics drive biotech momentum $MDNAF's"
@Gantosj on X 2025-05-20 15:39:23 UTC 13.3K followers, 5770 engagements

"So what we should look at from $CRDL's acute #myocarditis Ph-2 data The X primary outcome measures of the trial which were evaluated following XX weeks of double-blind therapy consist of cardiac MRI parameters: global longitudinal strain and extra-cellular volume which assess myocardial function and tissue characteristics associated with fibrosis and inflammation. Both parameters are recognized prognostic markers in patients with acute myocarditis"
@Gantosj on X 2025-07-22 12:58:26 UTC 13.3K followers, 8519 engagements

"$CRDL There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis. Acute #myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain shortness of breath fatigue rapid or irregular heartbeat (arrhythmias) and light-headedness and can lead to heart failure or sudden cardiac death"
@Gantosj on X 2025-07-22 11:38:59 UTC 13.3K followers, 3541 engagements

"$SRPT is eligible to receive up to $103.5M in near-term regulatory and commercial milestone payments Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS a Gene Therapy to Treat Duchenne Muscular Dystrophy"
@Gantosj on X 2025-05-13 13:47:36 UTC 13.3K followers, 2764 engagements

"$CRDL is getting close to release the Myocarditis data and continue with the positive momentum after the bounce off the 50MA Next target is the 200MA around $XXXX after breaking out the $XXXX resistanc eline"
@Gantosj on X 2025-06-03 16:28:58 UTC 13.3K followers, 7410 engagements

"Things are starting to get real. The FDA has now acknowledged a connection between COVID-19 vaccines and the increase in pericarditis and myocarditis cases among young people. On the bright side it's great to see $CRDL making solid progress with their #Pericarditis study already deep into Ph-3. Next important step Release the #Myocarditis data and see if they can build on their pericarditis success Potentially unlocking another major therapeutic win 🤞"
@Gantosj on X 2025-07-21 19:00:13 UTC 13.3K followers, 2667 engagements

"I look at it in a different way Dr. Garnett wouldnt be joining $CRDL's Board unless he saw major potential ahead and its clear hes excited about the prospects of Acute Pericarditis as it advances into the Phase X trial"
@Gantosj on X 2025-05-29 14:25:27 UTC 13.3K followers, 2316 engagements

"@semodough $SRPT Skorney touch the same point I mentioned today No serious adverse events in the X recently dosed patients but $SLDB did note that lab abnormalities including a transient decline in platelet count that was managed according to protocol assume is intervention with Soliris"
@Gantosj on X 2018-11-13 17:37:10 UTC 13.3K followers, XX engagements